ARTICLE | Clinical News
DCC-3014: Ph I started
March 10, 2017 7:56 PM UTC
Deciphera began an open-label, dose-escalation, dose-expansion, U.S. Phase I trial to evaluate once-daily DCC-3014, starting at a 10 mg dose, in 28-day cycles in up to 55 patients. Malignancies includ...
BCIQ Company Profiles
BCIQ Target Profiles
Colony-stimulating factor 1 receptor (CSF1R) (C-FMS) (CD115)